GoodRx

Recent news

• Rating change
  TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $5
  Market Newswire · 2026/8/13
• GoodRx(GDRX.US) 10% Shareholder Sells US$4.2 Million in Common Stock
  Market Newswire · 2026/8/22
• Rating change
  Raymond James Maintains GoodRx(GDRX.US) With Buy Rating, Announces Target Price $4.5
  Market Newswire · 2026/8/7
• Rating change
  Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $3.5
  Market Newswire · 2026/6/2
• Rating change
  A Quick Look at Today's Ratings for GoodRx(GDRX.US), With a Forecast Between $4 to $5
  Market Newswire · 2026/8/7
• Rating change
  TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Raises Target Price to $5
  Market Newswire · 2026/8/11
• GoodRx(GDRX.US) 10% Shareholder Sells US$5.48 Million in Common Stock
  Market Newswire · 2026/8/27
• Rating change
  Citi Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $4
  Market Newswire · 2026/7/23
• Rating change
  Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), MBX Biosciences, Inc. (MBX) and GoodRx Holdings (GDRX)
  TipRanks · 2026/6/10
• Rating change
  Goldman Sachs Maintains GoodRx(GDRX.US) With Hold Rating, Raises Target Price to $4
  Market Newswire · 2026/8/8
• Rating change
  Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating
  Market Newswire · 2026/8/14
• Rating change
  TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $4
  Market Newswire · 2026/5/11
• UBS Maintains GoodRx(GDRX.US) With Hold Rating, Raises Target Price to $3.75
  Market Newswire · 2026/8/13
• Rating change
  Morgan Stanley Maintains GoodRx(GDRX.US) With Hold Rating, Raises Target Price to $4
  Market Newswire · 2026/8/8
• BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Raises Target Price to $2.65
  Market Newswire · 2026/8/26
• BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $2.65
  Market Newswire · 2026/9/16
• Rating change
  Citi Maintains GoodRx(GDRX.US) With Buy Rating, Raises Target Price to $4
  Market Newswire · 2026/5/14
• Rating change
  Citi Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $5
  Market Newswire · 2026/8/11
• Rating change
  Analysts' Opinions Are Mixed on These Healthcare Stocks: GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen Inc. (PEPG)
  TipRanks · 2026/8/6
• Rating change
  Citi Maintains GoodRx(GDRX.US) With Buy Rating, Raises Target Price to $5
  Market Newswire · 2026/8/11

Headlines are aggregated automatically and are not independently verified or edited by our team.